Log In
BCIQ
Print this Print this
 

CMB305, ID-CMB305

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionCombination of LV305, a lentiviral vector engineered to deliver RNA for cancer/testis antigen 1B (NY-ESO-1; CTAG1B) to dendritic cells in vivo, and G305, an immunotherapy comprising recombinant NY-ESO-1 protein and the GLA-SE adjuvant
Molecular Target
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/12/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today